Literature DB >> 1694156

Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP.

A P Anselmo1, C Cartoni, P Bellantuono, R Maurizi-Enrici, N Aboulkair, M Ermini.   

Abstract

The gonadal function of 38 patients with Hodgkin's disease (HD) treated with MOPP chemotherapy (12 patients), ABVD (9 patients) and alternating MOPP/ABVD (17 patients) has been retrospectively investigated with semen analysis. Median age of patients was 25 years (range 16-41 years). Azoospermia was found in all patients from the MOPP group (100%), in 3 of the ABVD group (33%) and in 13 of the MOPP/ABVD group (76%). After temporary oligospermia full recovery of spermatogenesis was observed in 67% of patients treated with ABVD, versus 25% of MOPP-treated patients following a prolonged period of azoospermia and oligospermia. Patients receiving MOPP/ABVD scheme had complete recovery of testicular function after oligospermia in 24% of cases. These results confirm the higher gonadal toxicity of the MOPP regimen as compared to others such as ABVD without alkylating agents.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1694156

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  6 in total

1.  BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group.

Authors:  Kara M Kelly; Richard Sposto; Raymond Hutchinson; Vickie Massey; Kathleen McCarten; Sherrie Perkins; Mark Lones; Doojduen Villaluna; Michael Weiner
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

2.  Luteinizing hormone pulsatility and computer-assisted analysis of sperm features in patients with Hodgkin's disease.

Authors:  M Magnanti; S Malizia; G Garufi; A Lenzi; A P Anselmo; F Beligotti; A Fabbrini; V Santiemma
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Long-term survivorship at a price: late-term, therapy-associated toxicities in the adult hodgkin lymphoma patient.

Authors:  David J Straus
Journal:  Ther Adv Hematol       Date:  2011-04

4.  Post-treatment parenthood in Hodgkin's lymphoma survivors.

Authors:  C E Kiserud; A Fosså; H Holte; S D Fosså
Journal:  Br J Cancer       Date:  2007-04-03       Impact factor: 7.640

Review 5.  Fertility preservation in Hodgkin's lymphoma patients that undergo targeted molecular therapies: an important step forward from the chemotherapy era.

Authors:  Alexandra Traila; Patriciu Achimas-Cadariu; Delia Dima; Romeo Micu
Journal:  Cancer Manag Res       Date:  2018-06-13       Impact factor: 3.989

Review 6.  Nonclonal Chromosome Aberrations and Genome Chaos in Somatic and Germ Cells from Patients and Survivors of Hodgkin Lymphoma.

Authors:  Sara Frias; Sandra Ramos; Consuelo Salas; Bertha Molina; Silvia Sánchez; Roberto Rivera-Luna
Journal:  Genes (Basel)       Date:  2019-01-10       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.